CClinicalTrials.gg
CompletedNCT06735469Updated Sep 11, 2025

Clinical Trial Preference Study

An observational study in Clinical Trials, sponsored by Rush University Medical Center. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-11.

Sponsored by Rush University Medical Center · Observational

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
801
Ages
18 Years and older
Sex
All
01

Study summary

Population subgroups experiencing health disparities are often also underrepresented in clinical trials. These groups include individuals from minoritized racial and ethnic groups, people from lower socioeconomic backgrounds, and men or women, depending on the study area. Identifying approaches to reduce health disparities will remain stalled until clinical trials can recruit and retain diverse clinical trial participants. To improve recruitment across studies, there is a need to understand how diverse populations view specific clinical trial attributes that could be manipulated to increase interest in trials. To address this need, this project will use a discrete choice experiment to identify and prioritize specific trial attributes under investigators' control that could be leveraged to enhance clinical trial participation rates in underrepresented groups. This project will evaluate participants' preferences of 1) return of full versus limited results to participants, 2) balancing a study's participant burden with its ability to address multiple research aims, 3) incentivizing clinical assessments vs. conducting homebased assessments, and 4) results generalizable to specific social groups versus the broader population. This experiment will be conducted with a sample of potential clinical trial participants (N = 800) that is diverse in terms of self-reported gender, racial and ethnic identity, education, and chronic disease status. The results of this study will be used to design a randomized comparison of enhanced clinical trial attributes across multiple health conditions to evaluate whether using the enhanced trial features can more efficiently recruit underrepresented participants into clinical trials.

02

Conditions studied

  • Clinical Trials
03

In context

Lead sponsor

Rush University Medical Center is the lead sponsor of 394 studies on the registry; 61 are open to participants now.

Of its 30 completed or terminated interventional studies of FDA-regulated products, 25 (83%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

United States adults

Inclusion criteria

  • Internet access with audio and visual capabilities
  • Reside within the United States
  • Read and speak English

Exclusion criteria

Exclusion Criteria:

  • Under 18 years of age
  • No internet access
  • Reside outside of the United States
  • Do not read and speak English
05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
801 participants (actual)
Patient registry
No

Interventions

  • OtherDiscrete choice experiment

    Participants will state their preferences for 1) return of full versus limited results to participants (trust/personal benefit), 2) balancing a study's participant burden with the study's ability to address multiple research aims (burden/knowledge generation), 3) incentivizing clinical assessments vs. conducting home-based assessments (personal benefit/burden), and 4) results generalizable to specific social groups versus the broader population. Participants will evaluate these attributes within a hypothetical trial to prevent chronic diseases.

06

What researchers measure

Primary outcomes

  1. Participant preference for clinical trial attributes

    Utility values generated from multinomal logit estimates from a discrete choice experiment of 8 hypothetical choices (Trial A, B, or neither).

    Time frame: Baseline

07

Study locations

1 site
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
08

References and documents

Individual participant data

Plan to share: Undecided — Data will be made available in the Open Science Framework. Data will be made available as soon as possible after the data collection period has ended and will occur after the study investigators have had reasonable time to prepare manuscripts.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06735469
Lead sponsor
Rush University Medical Center
Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Responsible party
Melissa M. Crane, PhD (Assistant Professor, Rush University Medical Center) — Principal investigator
First posted
Dec 16, 2024
Start date
May 28, 2025
Primary completion
Sep 4, 2025
Completion
Sep 4, 2025
Last update
Sep 11, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion